Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung

Research output: Contribution to journalArticle

Abstract

Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to investigate the clinical outcomes of modifying the dose of melphalan-prednisone (MP) in patients receiving VMP. Methods: We examined 67 patients who received a modified dose of MP, and 38 patients who received the regularly planned dose of MP. We then analyzed clinical differences between the groups. Results: Although there was no difference in the proportion of discontinuation due to adverse events between dose groups, more patients in the planned-dose group experienced earlier discontinuation in general. The overall response rate (ORR) was 81.0% and complete response (CR) rate was 30.5%. After a median 15.7 months of follow-up, the median progression-free survival (PFS) and overall survival (OS) were 25.0 and 47.8 months, respectively. There was no significant difference in the ORR, CR, PFS, and OS of the two dose groups. A median of four cycles were delivered, and the median cumulative bortezomib dose was 41.6 mg/m2 . The median PFS in patients with doses ≥ 41.6 mg/m2 was longer than that in patients with doses < 41.6 mg/m2 (35.1 months vs. 9.6 months). However, when MP was < 50% of the planned dose, PFS and OS were poor. Conclusions: Modifying the dose of MP might be a feasible and effective therapeutic approach for multiple myeloma patients receiving VMP treatment.

Original languageEnglish
Pages (from-to)1333-1346
Number of pages14
JournalKorean Journal of Internal Medicine
Volume34
Issue number6
DOIs
Publication statusPublished - 2019 Nov

Fingerprint

Melphalan
Prednisone
Multiple Myeloma
Disease-Free Survival
Therapeutics
Survival
Bortezomib

Keywords

  • Bortezomib
  • Melphalan
  • Modified
  • Multiple myeloma
  • Prednisone

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{7065d84633c84fada23c22a6cece6b2f,
title = "Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment",
abstract = "Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to investigate the clinical outcomes of modifying the dose of melphalan-prednisone (MP) in patients receiving VMP. Methods: We examined 67 patients who received a modified dose of MP, and 38 patients who received the regularly planned dose of MP. We then analyzed clinical differences between the groups. Results: Although there was no difference in the proportion of discontinuation due to adverse events between dose groups, more patients in the planned-dose group experienced earlier discontinuation in general. The overall response rate (ORR) was 81.0{\%} and complete response (CR) rate was 30.5{\%}. After a median 15.7 months of follow-up, the median progression-free survival (PFS) and overall survival (OS) were 25.0 and 47.8 months, respectively. There was no significant difference in the ORR, CR, PFS, and OS of the two dose groups. A median of four cycles were delivered, and the median cumulative bortezomib dose was 41.6 mg/m2 . The median PFS in patients with doses ≥ 41.6 mg/m2 was longer than that in patients with doses < 41.6 mg/m2 (35.1 months vs. 9.6 months). However, when MP was < 50{\%} of the planned dose, PFS and OS were poor. Conclusions: Modifying the dose of MP might be a feasible and effective therapeutic approach for multiple myeloma patients receiving VMP treatment.",
keywords = "Bortezomib, Melphalan, Modified, Multiple myeloma, Prednisone",
author = "Lee, {Se Ryeon} and Hojoon Choi and Lee, {Byung Hyun} and Kang, {Ka Won} and Yu, {Eun Sang} and Kim, {Dae Sik} and Yong Park and Choi, {Chul Won} and Kim, {Byung Soo} and Sung, {Hwa Jung}",
year = "2019",
month = "11",
doi = "10.3904/kjim.2018.144",
language = "English",
volume = "34",
pages = "1333--1346",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "6",

}

TY - JOUR

T1 - Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

AU - Lee, Se Ryeon

AU - Choi, Hojoon

AU - Lee, Byung Hyun

AU - Kang, Ka Won

AU - Yu, Eun Sang

AU - Kim, Dae Sik

AU - Park, Yong

AU - Choi, Chul Won

AU - Kim, Byung Soo

AU - Sung, Hwa Jung

PY - 2019/11

Y1 - 2019/11

N2 - Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to investigate the clinical outcomes of modifying the dose of melphalan-prednisone (MP) in patients receiving VMP. Methods: We examined 67 patients who received a modified dose of MP, and 38 patients who received the regularly planned dose of MP. We then analyzed clinical differences between the groups. Results: Although there was no difference in the proportion of discontinuation due to adverse events between dose groups, more patients in the planned-dose group experienced earlier discontinuation in general. The overall response rate (ORR) was 81.0% and complete response (CR) rate was 30.5%. After a median 15.7 months of follow-up, the median progression-free survival (PFS) and overall survival (OS) were 25.0 and 47.8 months, respectively. There was no significant difference in the ORR, CR, PFS, and OS of the two dose groups. A median of four cycles were delivered, and the median cumulative bortezomib dose was 41.6 mg/m2 . The median PFS in patients with doses ≥ 41.6 mg/m2 was longer than that in patients with doses < 41.6 mg/m2 (35.1 months vs. 9.6 months). However, when MP was < 50% of the planned dose, PFS and OS were poor. Conclusions: Modifying the dose of MP might be a feasible and effective therapeutic approach for multiple myeloma patients receiving VMP treatment.

AB - Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to investigate the clinical outcomes of modifying the dose of melphalan-prednisone (MP) in patients receiving VMP. Methods: We examined 67 patients who received a modified dose of MP, and 38 patients who received the regularly planned dose of MP. We then analyzed clinical differences between the groups. Results: Although there was no difference in the proportion of discontinuation due to adverse events between dose groups, more patients in the planned-dose group experienced earlier discontinuation in general. The overall response rate (ORR) was 81.0% and complete response (CR) rate was 30.5%. After a median 15.7 months of follow-up, the median progression-free survival (PFS) and overall survival (OS) were 25.0 and 47.8 months, respectively. There was no significant difference in the ORR, CR, PFS, and OS of the two dose groups. A median of four cycles were delivered, and the median cumulative bortezomib dose was 41.6 mg/m2 . The median PFS in patients with doses ≥ 41.6 mg/m2 was longer than that in patients with doses < 41.6 mg/m2 (35.1 months vs. 9.6 months). However, when MP was < 50% of the planned dose, PFS and OS were poor. Conclusions: Modifying the dose of MP might be a feasible and effective therapeutic approach for multiple myeloma patients receiving VMP treatment.

KW - Bortezomib

KW - Melphalan

KW - Modified

KW - Multiple myeloma

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=85074423630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074423630&partnerID=8YFLogxK

U2 - 10.3904/kjim.2018.144

DO - 10.3904/kjim.2018.144

M3 - Article

C2 - 30360024

AN - SCOPUS:85074423630

VL - 34

SP - 1333

EP - 1346

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 6

ER -